A glucose carbonate apatite complex exhibits in vitro and in vivo anti-tumour effects

Hirofumi Yamamoto, Xin Wu, Hiroyuki Nakanishi, Yuki Yamamoto, Mamoru Uemura, Taishi Hata, Junichi Nishimura, Ichiro Takemasa, Tsunekazu Mizushima, Jun Ichi Sasaki, Satoshi Imazato, Nariaki Matsuura, Yuichiro Doki, Masaki Mori

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Tumour targeting nanotechnology has recently made therapeutic progress and several therapeutic nanoparticles have been approved for clinical application. However, an ideal nanotechnology based therapeutic for solid tumours, particularly for systemic administration, still remains a challenge in clinical cancer therapy. Wepreviously reported a pHsensitive in vivo delivery system of doxorubicin, or microRNA, using carbonate apatite (CA) nanoparticles. To further explore utility of CA in cancer therapy, we attempted to transport excess glucose into tumour cells by conjugating glucose (Glc) to the nanoparticle. Despite the non-toxicity of CA and Glc, the complex (CA-[Glc]) exhibited an unexpected anti-cancer effect in vitro and in vivo. CA-[Glc] significantly reduced the growth of colon cancer cell lines. Intravenous injections successfully suppressed solid tumour growth. In mice and monkeys, intravenously injected CA-[Glc] complex resulted in no serious abnormalities in body weight or blood chemistry. Because cancer cells intensively metabolise glucose than normal cells, treatment of cancer using glucose seems paradoxical. However, with the aid of CA, this safe and 'sweet' complex may be a novel anti-cancer reagent.

Original languageEnglish
Article number7742
JournalScientific reports
Volume5
DOIs
Publication statusPublished - Jan 1 2015
Externally publishedYes

Fingerprint

Glucose
Neoplasms
Nanoparticles
Nanotechnology
Therapeutics
In Vitro Techniques
carboapatite
Growth
MicroRNAs
Intravenous Injections
Doxorubicin
Colonic Neoplasms
Haplorhini
Body Weight
Cell Line

All Science Journal Classification (ASJC) codes

  • General

Cite this

A glucose carbonate apatite complex exhibits in vitro and in vivo anti-tumour effects. / Yamamoto, Hirofumi; Wu, Xin; Nakanishi, Hiroyuki; Yamamoto, Yuki; Uemura, Mamoru; Hata, Taishi; Nishimura, Junichi; Takemasa, Ichiro; Mizushima, Tsunekazu; Sasaki, Jun Ichi; Imazato, Satoshi; Matsuura, Nariaki; Doki, Yuichiro; Mori, Masaki.

In: Scientific reports, Vol. 5, 7742, 01.01.2015.

Research output: Contribution to journalArticle

Yamamoto, H, Wu, X, Nakanishi, H, Yamamoto, Y, Uemura, M, Hata, T, Nishimura, J, Takemasa, I, Mizushima, T, Sasaki, JI, Imazato, S, Matsuura, N, Doki, Y & Mori, M 2015, 'A glucose carbonate apatite complex exhibits in vitro and in vivo anti-tumour effects', Scientific reports, vol. 5, 7742. https://doi.org/10.1038/srep07742
Yamamoto H, Wu X, Nakanishi H, Yamamoto Y, Uemura M, Hata T et al. A glucose carbonate apatite complex exhibits in vitro and in vivo anti-tumour effects. Scientific reports. 2015 Jan 1;5. 7742. https://doi.org/10.1038/srep07742
Yamamoto, Hirofumi ; Wu, Xin ; Nakanishi, Hiroyuki ; Yamamoto, Yuki ; Uemura, Mamoru ; Hata, Taishi ; Nishimura, Junichi ; Takemasa, Ichiro ; Mizushima, Tsunekazu ; Sasaki, Jun Ichi ; Imazato, Satoshi ; Matsuura, Nariaki ; Doki, Yuichiro ; Mori, Masaki. / A glucose carbonate apatite complex exhibits in vitro and in vivo anti-tumour effects. In: Scientific reports. 2015 ; Vol. 5.
@article{eef8343547534319b880a462eb587e3c,
title = "A glucose carbonate apatite complex exhibits in vitro and in vivo anti-tumour effects",
abstract = "Tumour targeting nanotechnology has recently made therapeutic progress and several therapeutic nanoparticles have been approved for clinical application. However, an ideal nanotechnology based therapeutic for solid tumours, particularly for systemic administration, still remains a challenge in clinical cancer therapy. Wepreviously reported a pHsensitive in vivo delivery system of doxorubicin, or microRNA, using carbonate apatite (CA) nanoparticles. To further explore utility of CA in cancer therapy, we attempted to transport excess glucose into tumour cells by conjugating glucose (Glc) to the nanoparticle. Despite the non-toxicity of CA and Glc, the complex (CA-[Glc]) exhibited an unexpected anti-cancer effect in vitro and in vivo. CA-[Glc] significantly reduced the growth of colon cancer cell lines. Intravenous injections successfully suppressed solid tumour growth. In mice and monkeys, intravenously injected CA-[Glc] complex resulted in no serious abnormalities in body weight or blood chemistry. Because cancer cells intensively metabolise glucose than normal cells, treatment of cancer using glucose seems paradoxical. However, with the aid of CA, this safe and 'sweet' complex may be a novel anti-cancer reagent.",
author = "Hirofumi Yamamoto and Xin Wu and Hiroyuki Nakanishi and Yuki Yamamoto and Mamoru Uemura and Taishi Hata and Junichi Nishimura and Ichiro Takemasa and Tsunekazu Mizushima and Sasaki, {Jun Ichi} and Satoshi Imazato and Nariaki Matsuura and Yuichiro Doki and Masaki Mori",
year = "2015",
month = "1",
day = "1",
doi = "10.1038/srep07742",
language = "English",
volume = "5",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - A glucose carbonate apatite complex exhibits in vitro and in vivo anti-tumour effects

AU - Yamamoto, Hirofumi

AU - Wu, Xin

AU - Nakanishi, Hiroyuki

AU - Yamamoto, Yuki

AU - Uemura, Mamoru

AU - Hata, Taishi

AU - Nishimura, Junichi

AU - Takemasa, Ichiro

AU - Mizushima, Tsunekazu

AU - Sasaki, Jun Ichi

AU - Imazato, Satoshi

AU - Matsuura, Nariaki

AU - Doki, Yuichiro

AU - Mori, Masaki

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Tumour targeting nanotechnology has recently made therapeutic progress and several therapeutic nanoparticles have been approved for clinical application. However, an ideal nanotechnology based therapeutic for solid tumours, particularly for systemic administration, still remains a challenge in clinical cancer therapy. Wepreviously reported a pHsensitive in vivo delivery system of doxorubicin, or microRNA, using carbonate apatite (CA) nanoparticles. To further explore utility of CA in cancer therapy, we attempted to transport excess glucose into tumour cells by conjugating glucose (Glc) to the nanoparticle. Despite the non-toxicity of CA and Glc, the complex (CA-[Glc]) exhibited an unexpected anti-cancer effect in vitro and in vivo. CA-[Glc] significantly reduced the growth of colon cancer cell lines. Intravenous injections successfully suppressed solid tumour growth. In mice and monkeys, intravenously injected CA-[Glc] complex resulted in no serious abnormalities in body weight or blood chemistry. Because cancer cells intensively metabolise glucose than normal cells, treatment of cancer using glucose seems paradoxical. However, with the aid of CA, this safe and 'sweet' complex may be a novel anti-cancer reagent.

AB - Tumour targeting nanotechnology has recently made therapeutic progress and several therapeutic nanoparticles have been approved for clinical application. However, an ideal nanotechnology based therapeutic for solid tumours, particularly for systemic administration, still remains a challenge in clinical cancer therapy. Wepreviously reported a pHsensitive in vivo delivery system of doxorubicin, or microRNA, using carbonate apatite (CA) nanoparticles. To further explore utility of CA in cancer therapy, we attempted to transport excess glucose into tumour cells by conjugating glucose (Glc) to the nanoparticle. Despite the non-toxicity of CA and Glc, the complex (CA-[Glc]) exhibited an unexpected anti-cancer effect in vitro and in vivo. CA-[Glc] significantly reduced the growth of colon cancer cell lines. Intravenous injections successfully suppressed solid tumour growth. In mice and monkeys, intravenously injected CA-[Glc] complex resulted in no serious abnormalities in body weight or blood chemistry. Because cancer cells intensively metabolise glucose than normal cells, treatment of cancer using glucose seems paradoxical. However, with the aid of CA, this safe and 'sweet' complex may be a novel anti-cancer reagent.

UR - http://www.scopus.com/inward/record.url?scp=84922566570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922566570&partnerID=8YFLogxK

U2 - 10.1038/srep07742

DO - 10.1038/srep07742

M3 - Article

VL - 5

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 7742

ER -